Iovance Biotherapeutics (IOVA) Jefferies Global Healthcare Conference summary
Event summary combining transcript, slides, and related documents.
Jefferies Global Healthcare Conference summary
16 Nov, 2026Commercial launch and market opportunity
Q3 2026 sales reached $122M for AMTAGVI and PROLEUKIN; FY 2025 sales were $264M, and 9M 2026 revenue was $292M.
ATC expansion remains a priority; at least 110 centers are targeted by year-end 2026, with management on track to meet or exceed that goal.
U.S. second-line-plus metastatic melanoma represents ~8,500 patients; first-line melanoma exceeds 22,000, while non-squamous lung market potential is 7x melanoma’s.
AMTAGVI is approved in the U.S., Canada and Australia; Switzerland and U.K. approvals are expected in Q1 2027, with an EU resubmission planned.
Philadelphia manufacturing can scale through existing modular capacity; cryopreserved product has a 12-month shelf life, and new facilities are not in immediate plans.
Financial outlook and operations
FY 2026 revenue guidance is $410M–$420M; management said it feels in good shape and expects continued growth from treating more patients.
Q3 gross margin was 60%, with 9M margin at 54%; long-term goal remains 70% or higher, without a specified timeframe.
Cost control and plant efficiencies are supporting margin improvement; quarterly results may vary, while management expects longer-term progress.
January 1, 2027 price increases: 9% for AMTAGVI and 7% for PROLEUKIN; reported cash balance was $382M at the end of the last reported quarter.
Prior plant upgrades are expected to prevent routine maintenance from disrupting production; clinical trials and operating expenses are being managed with financial discipline.
Melanoma development
Phase III TILVANCE-301 serves as the U.S. accelerated-approval confirmatory trial and supports potential first-line accelerated and eventual confirmatory approvals; enrollment is well underway.
Recent first-line phase II data showed an ORR above 60% and a notably high complete-response rate; final data cut is complete and a manuscript is in preparation.
Management plans to share more melanoma data; second-line patients treated with two or fewer prior lines had response rates above 50%, and five-year data showed median overall survival exceeding 36 months.
Latest events from Iovance Biotherapeutics
- Record Q3 revenue and ~60% gross margin as Amtagvi adoption and registrational trials advanced.IOVA
Q3 2026 - Durable melanoma responses anchor a growing solid-tumor TIL pipeline.IOVA
Corporate presentation - Lifileucel achieved a 59.1% ORR in the biomarker-enriched mNSCLC subgroup.IOVA
Study update - Record revenue and strong clinical results drive expansion and innovation in TIL therapy.IOVA
H.C. Wainwright 28th Annual Global Investment Conference - Strong sales growth, expanding clinical pipeline, and operational efficiencies support long-term outlook.IOVA
Wells Fargo 21st Annual Healthcare Conference - Q2 2026 revenue surged 66% to $99.3M, margin hit 56%, and cash reserves support ongoing growth.IOVA
Q2 2026 - Strong revenue growth and durable TIL therapy efficacy drive expansion in solid tumor oncology.IOVA
Corporate presentation - Five-year data confirm durable survival and expanding access for one-time TIL cell therapy in melanoma.IOVA
KOL event - Q1 2025 revenue was $49.3M; FY25 guidance is $250–$300M with global expansion underway.IOVA
Q1 2025